Abstract 101P
Background
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Despite the availability of multiple treatment strategies, the prognosis of the patients with CRC is dismal. The aim of this study is to evaluate the efficacy and safety of cellular immunotherapy (CIT) (the use of autologous natural killer cells, γδTcells and cytokine-induced killer cells) in combination with chemotherapy in patients with CRC.
Methods
A retrospective analysis of 377 patients with colorectal adenocarcinoma from December 2010 to December 2015 was performed, including 97 patients in the CIT+chemotherapy group and 280 patients in the chemotherapy group. The primary endpoints were DFS or PFS (Patients with adjuvant therapy after radical resection of colorectal cancer had the same DFS as PFS). The secondary endpoints were OS, ORR, DCR, adverse reaction rate and treatment tolerance.
Results
The 3-year progression-free survival rate of CIT+chemotherapy group and chemotherapy group was 67.2% vs 53.9% (P < 0.01), and the 5-year OS rate was 74.1% vs 50.8% (P < 0.001). CIT+chemotherapy was independent prognostic factors for both DFS (HR: 0.618, 95% CI: 0.428–0.891) and OS (HR: 0.513, 95% CI: 0.335–0.784). The ORR and DCR of CRC patients with IV staging in the CIT+chemotherapy compared to chemotherapy group were 63.0% vs 50.8% (P = 0.291) and 81.5% vs 65.6% (P = 0.131) respectively. The percentage of CD3+, CD3+ CD4+ cell subsets were significantly increased from 70.11% to 75.87% (P < 0.01), and 42.53% to 44.39% (P = 0.02) in the CIT+chemotherapy group after treatment. Overall adverse reaction rate of CIT+chemotherapy group and chemotherapy group was 75.3% vs 75.4% (P = 0.98) respectively. In patients with stage III, the median chemotherapy course in CIT +chemotherapy compared to chemotherapy group is 8 vs 6 (P = 0.003).
Conclusions
High quality and standardized CIT combined with chemotherapy can promote the survival time, reduce the recurrence rate and improve the immune status of CRC patients. In addition, it is safe and low-toxic which improves the patient's tolerance to chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract